On May 13, 2014, Aratana Therapeutics Inc (NASDAQ:PETX) announced its first quarter 2014 financial results. For the three months ended March 31, 2014, Aratana reported a net loss of ($9.2) million, or ($0.34) basic and diluted earnings per share compared to a loss of ($3.3) million for the same period in 2013. Aratana Therapeutics Inc (NASDAQ:PETX) weekly performance is 5.56%. On last trading day company shares ended up $12.35. Analysts mean target price for the company is $30.60. Aratana Therapeutics Inc (NASDAQ:PETX) distance from 50-day simple moving average (SMA50) is -21.45%.
On May 14, ANI Pharmaceuticals Inc (NASDAQ:ANIP) files to sell 3.5M shares of common stock for holders. ANI Pharmaceuticals Inc (NASDAQ:ANIP) shares fell -2.65% in last trading session and ended the day on $27.21. ANIP Gross Margin is 66.80% and its return on assets is -17.00%. ANI Pharmaceuticals Inc (NASDAQ:ANIP) quarterly performance is 26.73%.
May 13, 2014 Prosensa Holding NV (NASDAQ:RNA) announced that the Company will host a conference call and live audio webcast on Tuesday, May 20, 2014 at 8:00 a.m. US Eastern Time (2:00 p.m. Central European Time) to report its first quarter financial results and provide a corporate update. Prosensa Holding NV (NASDAQ:RNA) shares moved down -2.40% in last trading session and was closed at $6.10, while trading in range of $6.00 – $6.53. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 30.62%.
On May 13, 2014, CorMedix Inc. (NYSEMKT:CRMD) announced that a conference call will be held on Friday, May 16, 2014 at 9:00 a.m. ET to discuss the Company’s first quarter 2014 results. Randy Milby, Chief Executive Officer of CorMedix, will host the call on Friday, May 16th at 9:00 AM ET. The first quarter 2014 financial results will be released on May 15th. CorMedix Inc. (NYSEMKT:CRMD) ended the last trading day at $1.55. Company weekly volatility is calculated as 11.89% and price to cash ratio as 14.21. CorMedix Inc. (NYSEMKT:CRMD) showed a negative weekly performance of -10.92%.
On May 14, Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced the appointment of Chris Bowden, M.D., to the newly created position of chief medical officer, where he will oversee global clinical development and regulatory initiatives for Agios. Bowden, who brings more than 17 years of experience in clinical drug development, including the approval of several cancer medicines, was previously vice president, product development oncology, franchise lead at Genentech, a member of the Roche Group (RHHBY). Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares advanced 0.15% in last trading session and ended the day on $33.23. AGIO return on assets is -31.90%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly performance is 3.78%.